PARP inhibitors in prostate cancer: time to narrow patient selection?

Expert Rev Anticancer Ther. 2020 Jul;20(7):523-526. doi: 10.1080/14737140.2020.1781622. Epub 2020 Jul 7.
No abstract available

Keywords: PARP inhibitors; metastatic castration-resistant prostate cancer; niraparib; olaparib; prostate cancer; rucaparib; talazoparib.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Male
  • Patient Selection*
  • Poly(ADP-ribose) Polymerase Inhibitors / administration & dosage
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
  • Poly(ADP-ribose) Polymerases / metabolism
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology

Substances

  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases